'Watch This Space' Roche Execs Say, Outlining RWE Rationale For Flatiron Buy
Executive Summary
Buying Flatiron Health offers research-quality electronic medical records data which will help gain access to patients and help in the drug development and reimbursement process, Roche exes say.
You may also be interested in...
Gilead Lures Roche Pharma CEO O'Day As CEO; Genentech's CEO Will Replace Him
O'Day brings Gilead experience in oncology and M&A from a large, diversified organization.
CEO Interview: Roche Pharma Head Daniel O'Day On R&D Strategy
In an interview with Scrip, Roche Pharma CEO Daniel O'Day emphasized the importance that personalized healthcare will have in transforming R&D and how patients are treated.
CEO Interview: Roche Pharma Head Daniel O'Day On R&D Strategy
In an interview with Scrip, Roche Pharma CEO Daniel O'Day emphasized the importance that personalized healthcare will have in transforming R&D and how patients are treated.